导管消融与抗心律失常药物治疗对房颤患者死亡率、卒中、出血和心脏骤停的影响:CABANA随机临床试验
CABANA为研究者发起的开放标签多中心随机试验,纳入10个国家126个中心的2204例症状性房颤患者(≥65岁或<65岁伴≥1项卒中危险因素),随机分为导管消融组(n=1108)与药物节律/率控制组(n=1096)。中位随访48.5个月,主要复合终点(死亡、致残性卒中、严重出血或心脏骤停)在消融组8.0%(89例)vs 药物组9.2%(101例),HR 0.86(95%CI 0.65-1.15),P=.30,未达统计学显著。次要终点中,全因死亡5.2% vs 6.1%(HR 0.85,95%CI 0.60-1.21,P=.38)无显著差异;死亡或心血管住院51.7% vs 58.1%(HR 0.83,95%CI 0.74-0.93,P=.001)及房颤复发49.9% vs 69.5%(HR 0.52,95%CI 0.45-0.60,P<.001)在消融组更低。作者指出,估计的治疗效应受低于预期的事件率与治疗交叉影响,解读结果时应予考虑。
要点
- 主要复合终点(死亡、致残性卒中、严重出血、心脏骤停):消融组8.0%(89例)vs 药物组9.2%(101例),HR 0.86(95%CI 0.65-1.15),P=.30,未达统计学显著。
- 全因死亡:消融组5.2% vs 药物组6.1%,HR 0.85(95%CI 0.60-1.21),P=.38,两组无显著差异。
- 死亡或心血管住院:消融组51.7% vs 药物组58.1%,HR 0.83(95%CI 0.74-0.93),P=.001,消融组更低。
- 房颤复发:消融组49.9% vs 药物组69.5%,HR 0.52(95%CI 0.45-0.60),P<.001,消融组更低。
- 意向治疗分析中,药物组有301例(27.5%)最终接受导管消融,消融组有1006例(90.8%)实际接受手术,交叉影响结果解读。
适用人群与场景
- 症状性房颤患者,年龄≥65岁,或<65岁且伴1项或以上卒中危险因素;2009年11月至2016年4月入组,随访至2017年12月31日。
- 随机分组:导管消融组n=1108,药物节律和/或率控制组n=1096;中位年龄68岁,女性37.2%,阵发性房颤42.9%、持续性房颤57.1%。
处置流程与药物剂量
- 导管消融组(n=1108)行肺静脉隔离,是否加做其他消融术式由各中心研究者决定。
- 药物组(n=1096)接受标准节律和/或率控制药物,按同期指南指导。
研究设计与关键结果
- 研究类型:研究者发起的开放标签多中心随机试验,10个国家126个中心,2204例症状性房颤患者,随机分为导管消融组(n=1108)与药物节律和/或率控制组(n=1096),89.3%完成试验。
- 主要终点(死亡、致残性卒中、严重出血或心脏骤停复合终点):意向治疗分析中位随访48.5个月,消融组8.0%(89例)vs 药物组9.2%(101例),HR 0.86(95%CI 0.65-1.15),P=.30。
- 全因死亡:消融组5.2% vs 药物组6.1%,HR 0.85(95%CI 0.60-1.21),P=.38。
- 死亡或心血管住院:消融组51.7% vs 药物组58.1%,HR 0.83(95%CI 0.74-0.93),P=.001。
- 房颤复发:消融组49.9% vs 药物组69.5%,HR 0.52(95%CI 0.45-0.60),P<.001。
证据类型、等级与局限
- 证据类型:随机对照试验(CABANA,ClinicalTrials.gov NCT00911508)。
- 局限:作者指出,导管消融的估计治疗效应受低于预期的事件率与治疗交叉影响,解读试验结果时应予考虑。
对床旁实践的改变
- 对症状性房颤且年龄≥65岁或<65岁伴≥1项卒中危险因素的患者,导管消融与药物节律和/或率控制相比,未显著降低死亡、致残性卒中、严重出血或心脏骤停的复合终点。
- 作者指出,估计的治疗效应受低于预期的事件率与治疗交叉影响,解读本试验结果时应予考虑。
- 意向治疗分析中药物组27.5%(301例)最终接受导管消融,解读结果时需考虑这一交叉。
指南或共识出处
- CABANA随机临床试验(ClinicalTrials.gov NCT00911508)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Catheter ablation is effective in restoring sinus rhythm in atrial fibrillation (AF), but its effects on long-term mortality and stroke risk are uncertain.
OBJECTIVE: To determine whether catheter ablation is more effective than conventional medical therapy for improving outcomes in AF.
DESIGN, SETTING, AND PARTICIPANTS: The Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation trial is an investigator-initiated, open-label, multicenter, randomized trial involving 126 centers in 10 countries. A total of 2204 symptomatic patients with AF aged 65 years and older or younger than 65 years with 1 or more risk factors for stroke were enrolled from November 2009 to April 2016, with follow-up through December 31, 2017.
INTERVENTIONS: The catheter ablation group (n = 1108) underwent pulmonary vein isolation, with additional ablative procedures at the discretion of site investigators. The drug therapy group (n = 1096) received standard rhythm and/or rate control drugs guided by contemporaneous guidelines.
MAIN OUTCOMES AND MEASURES: The primary end point was a composite of death, disabling stroke, serious bleeding, or cardiac arrest. Among 13 prespecified secondary end points, 3 are included in this report: all-cause mortality; total mortality or cardiovascular hospitalization; and AF recurrence.
RESULTS: Of the 2204 patients randomized (median age, 68 years; 37.2% female; 42.9% had paroxysmal AF and 57.1% had persistent AF), 89.3% completed the trial. Of the patients assigned to catheter ablation, 1006 (90.8%) underwent the procedure. Of the patients assigned to drug therapy, 301 (27.5%) ultimately received catheter ablation. In the intention-to-treat analysis, over a median follow-up of 48.5 months, the primary end point occurred in 8.0% (n = 89) of patients in the ablation group vs 9.2% (n = 101) of patients in the drug therapy group (hazard ratio [HR], 0.86 [95% CI, 0.65-1.15]; P = .30). Among the secondary end points, outcomes in the ablation group vs the drug therapy group, respectively, were 5.2% vs 6.1% for all-cause mortality (HR, 0.85 [95% CI, 0.60-1.21]; P = .38), 51.7% vs 58.1% for death or cardiovascular hospitalization (HR, 0.83 [95% CI, 0.74-0.93]; P = .001), and 49.9% vs 69.5% for AF recurrence (HR, 0.52 [95% CI, 0.45-0.60]; P < .001).
CONCLUSIONS AND RELEVANCE: Among patients with AF, the strategy of catheter ablation, compared with medical therapy, did not significantly reduce the primary composite end point of death, disabling stroke, serious bleeding, or cardiac arrest. However, the estimated treatment effect of catheter ablation was affected by lower-than-expected event rates and treatment crossovers, which should be considered in interpreting the results of the trial.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00911508.
参考来源
- Packer DL, Mark DB, Robb RA, et al. Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019. PMID: 30874766. doi:10.1001/jama.2019.0693
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。